Receptor crosslinking: a general method to trigger internalization and lysosomal targeting of therapeutic receptor: ligand complexes

Moody, Paul R. ORCID: https://orcid.org/0000-0002-0191-2912, Sayers, Edward J. ORCID: https://orcid.org/0000-0002-2621-1119, Magnusson, Johannes P., Alexander, Cameron, Borri, Paola ORCID: https://orcid.org/0000-0002-7873-3314, Watson, Peter ORCID: https://orcid.org/0000-0003-0250-7852 and Jones, Arwyn T. ORCID: https://orcid.org/0000-0003-2781-8905 2015. Receptor crosslinking: a general method to trigger internalization and lysosomal targeting of therapeutic receptor: ligand complexes. Molecular Therapy 23 (12) , pp. 1888-1898. 10.1038/mt.2015.178

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (2MB) | Preview

Abstract

A major unmet clinical need is a universal method for sub-cellular targeting of bioactive molecules to lysosomes. Delivery to this organelle enables either degradation of oncogenic receptors that are overexpressed in cancers, or release of prodrugs from antibody-drug conjugates. Here we describe a general method that uses receptor crosslinking to trigger endocytosis, and subsequently redirect trafficking of receptor:cargo complexes from their expected route, to lysosomes. By incubation of plasma membrane receptors with biotinylated cargo and subsequent addition of streptavidin to crosslink receptor:cargo-biotin complexes, we achieved rapid and selective lysosomal targeting of transferrin, an anti-MHC I antibody, and the clinically approved anti-Her2 antibody Trastuzumab. These three protein ligands each target a receptor with a distinct cellular function and intracellular trafficking profile. Importantly, we confirmed that crosslinking of Trastuzumab increased lysosomal degradation of its cognate oncogenic receptor Her2 in breast cancer cell lines SKBR3 and BT474. These data suggest that crosslinking could be exploited for a wide range of target receptors, for navigating therapeutics through the endolysosomal pathway, for significant therapeutic benefit.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy Biosciences
Additional Information:	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license
Publisher:	Elsevier (Cell Press)
ISSN:	1525-0016
Funders:	EPSRC
Date of First Compliant Deposit:	30 March 2016
Date of Acceptance:	1 September 2015
Last Modified:	06 Jan 2024 04:34
URI:	https://orca.cardiff.ac.uk/id/eprint/78334

Citation Data

Cited 65 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item